Abstract:CD20 targeted therapy by means of anti-CD20 mAb is currently the most important regimen for treating B cells malignancies. However, 1-2% of B-cell lymphoma patients test negative for CD20. Besides, it has been reported in several studies that CD20 expression was down-regulated in over 20% of CD20-positive DLBCL patients that had relapsed/progressed after R-CHOP regimen. The limited prognosis for these patients poses a substantial unmet medical need. A new class of "1:2" format CD3 x CD20 bispecific antibodies emerged aiming for increased tumor antigen avidity and enhanced tumor cell killing, however, its advantages over conventional "1:1" format CD3 x CD20 antibodies have yet to be revealed in clinical trials. CMG1A46 is a 151 KD IgG-like "1:(1+1)" tri-specific antibody constructed on Chimagen's TRIAD platform. It simultaneously targets CD3 on T cell and two different biomarkers - CD20 and CD19 (abundancy of which proven to be intact post CD20-targeted treatment) - on tumor cells, recruiting T cells to kill tumor cells expressing CD19 and/or CD20. CMG1A46 is designed to target not only conventional CD19+CD20+ DLBCL, but also CD20-CD19+ DLBCL and DLBCL with trace to low expression of CD20 owing to its high avidity for tumor cells from 2 binders for CD19 and CD20 respectively. In vitro, CMG1A46 was shown to mediate tumor cell lysis by human PBMCs in a dose-dependent manner with EC50 around 0.3 pM. CMG1A46 was shown to have superior potency and safety (based on target-independent T cell activation) when compared to CD3 x CD20 bispecific antibodies with the conventional "1:1" IgG-based format. The antibody was able to induce potent tumor lysis in cells expressing both CD19 and CD20, and in cells expressing CD19 or CD20 alone. In vivo, 1A46 displayed potent tumor-suppressing activity in human PBMC-engrafted NOD mouse models and induced fast regression of large (CD19+CD20+) Jeko-1 lymphoma and (CD19+CD20-) A20-hCD19 tumors of ~100mm3. Remarkably, CMG1A46 can be administrated at the dosage 6 times as high as conventional CD3 x CD20 bispecific antibodies (3mg/kg for CMG1A46, 0.5mg/kg for conventional) and conferred even higher anti-tumor potency without any noticeable increase in toxicity (as evidenced by body weight of the animals and cytokine levels/T cell counts in serum post last administration). Pharmacokinetic studies in cyno monkeys show that when administrated at 1mpk CMG1A46 has a half-life that is over 70 hours in serum. After initial induction doses, weekly administration is able to maintain high circulating levels of the molecule. Dosages up to 10mpk do not lead to significant adverse effects. CMG1A46 treatment resulted in fast and complete elimination of B cells in peripheral blood within 24 hours after the first administration. Peripheral B cell elimination sustained for at least 28 days after last administration at 1mpk. B cell depletion was paralleled by transient decrease of T-cell counts in the peripheral blood and by the peak of cytokine release 4-8 hours after the first administration, followed by rapid recovery and return to baseline levels at 24 hours post treatment. Accordingly, CD3 receptor occupancy (RO) transiently increased during the induction phase and fell back to and sustained at a low level of around 20-30%. These studies show that CMG1A46 is a novel CD19/CD20-targeting T cell-engaging tri-specific antibody with very promising anti-tumor activity. In both in vitro and in vivo experiments, CMG1A46 demonstrated superior potency and safety compared to other CD3 x CD20 bispecific antibodies with the conventional "1:1" IgG format. Preliminary study in cyno monkeys suggested IgG-like half-life in serum and manageable toxicity. Taken together, the preclinical data strongly support for clinical testing of CMG1A46 in patients with CD20+ cancers. Phase 1 trial of the molecule is scheduled to start by April 2021. Disclosures No relevant conflicts of interest to declare.

Conjugation of DM1 to Anti-Cd30 Antibody Has Potential Antitumor Activity in CD30-positive Hematological Malignancies with Lower Systemic Toxicity.

Preliminary biological evaluation of 123I-labelled anti-CD30-LDM in CD30-positive lymphomas murine models

Novel anti-CD30/CD3 bispecific antibodies activate human T cells and mediate potent anti-tumor activity

Antitumor activity of a 5T4 targeting antibody drug conjugate with a novel payload derived from MMAF via C-Lock linker.

Antibody-drug Conjugate PCMC1D3-Duocarmycin SA as a Novel Therapeutic Entity for Targeted Treatment of Cancers Aberrantly Expressing MET Receptor Tyrosine Kinase

Therapeutic Potential of an Anti-Her2 Single Chain Antibody–dm1 Conjugates for the Treatment of HER2-positive Cancer

Abstract 3139: BL-M11D1, a novel CD33-targeting ADC, demonstrates robust anti-tumor efficacy in preclinical evaluation

In vivo antitumor effects of unconjugated CD30 monoclonal antibodies on human anaplastic large-cell lymphoma xenografts.

Therapeutic Efficacy of a Novel Humanized Antibody-Drug Conjugate Recognizing Plexin-Semaphorin-integrin Domain in the RON Receptor for Targeted Cancer Therapy.

Preclinical characterization of a novel investigational monoclonal antibody CM313 with potent CD38-positive cell killing activity

Abstract 3131: Novel CDH17-targeting antibody-drug conjugate exhibits anti-tumor efficacy in preclinical models of gastrointestinal cancers

Targeting of DDR1 with Antibody‐drug Conjugates Has Antitumor Effects in a Mouse Model of Colon Carcinoma

Engineered Scpdl1-Dm1 Drug Conjugate with Improved in Vitro Analysis to Target PD-L1 Positive Cancer Cells and Intracellular Trafficking Studies in Cancer Therapy.

Results of a Phase 1/2 Study of MHB088C: A Novel B7H3 Antibody-Drug Conjugate (ADC) Incorporating a Potent DNA Topoisomerase I Inhibitor in Recurrent or Metastatic Solid Tumors.

Potent Activity of an Anti-ICAM1 Antibody–Drug Conjugate against Multiple Myeloma

Development and Characterization of a Novel Peptide—Drug Conjugate with DM1 for Treatment of FGFR2-Positive Tumors

Development of Next Generation Antibody-Polymer-Drug Conjugates for Treatment of Multiple Myeloma

Design, Synthesis and Evaluation of Anti-Cd38 Antibody Drug Conjugate Based on Daratumumab and Maytansinoid

Preclinical Study of a Novel Tri-Specific Anti-CD3/CD19/CD20 T Cell-Engaging Antibody As a Potentially Better Treatment for NHL

Novel Antibody-Drug Conjugates Based on DXd-ADC Technology

Abstract 1884: DXC006, Anti-CD56-CPT113 ADC displays favorable anti-tumor efficacy, pharmacokinetic and safety profiles in preclinical studies